Skip to main contentAI and Advanced
/
INDOUS · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
IN
NSE · Equity shares · Biotechnology & Drugs2.44 · 3.16%
Indo US Bio-Tech INDOUS
NSE:INR 79.6
BSE:INR 80.28
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for INDOUS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 77.16
Day rangeINR 76.1 — INR 81
52-week rangeINR 70 — INR 205.1
Volume3,837
Market cap170.53
P/E15.02
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)110.44
Net Income (INR Cr)13.12
Rev Growth (5 Year %)22.47
EPS Growth (5 Year %)13.31
P/E Ratio15.02
Book Value46.15
EPS6.54
Price/BV1.72Computed
Research path: Interpret Indo US Bio-Tech's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
INDOUSIndo US Bio-Tech1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 133.1 | 97.84 | 84.46 |
| Cash Equivalents | 6.12 | 0.25 | 1.1 |
| Other Liabilities Total | 0.09 | 0.05 | 1.44 |
| Long Term Debt | 0.95 | 2.93 | 2.8 |
| Common Stock Total | 20.05 | 20.05 | 20.05 |
| Other Current Assets Total | 0.07 | 0.04 | 0.03 |
| Total Assets | 133.1 | 97.84 | 84.46 |
| Current Portof LT Debt/Capital Leases | 36.08 | 1.53 | 1.14 |
| Total Equity | 92.53 | 78.52 | 62.75 |
| Retained Earnings(Accumulated Deficit) | 72.48 | 58.47 | 42.7 |
| Total Common Shares Outstanding | 2.01 | 2.01 | 2.01 |
| Tangible Book Valueper Share Common Eq | 46.15 | 39.16 | 31.29 |
| Total Liabilities | 40.56 | 19.32 | 21.71 |
| Total Debt | 37.04 | 14.84 | 14.32 |
| Short Term Investments | 0.79 | 0.75 | Not available |
| Cashand Short Term Investments | 6.91 | 1 | 1.1 |
| Total Receivables Net | 13.76 | 15 | 20.22 |
| Accounts Receivable-Trade Net | 13.76 | 15 | 19.05 |
| Property/Plant/Equipment Total-Net | 11.72 | 10.23 | 10.47 |
| Total Current Liabilities | 39.52 | 16.34 | 17.46 |
| Total Inventory | 99.95 | 70.69 | 51.74 |
| Accounts Payable | 0.45 | 1.16 | 4.39 |
| Other Currentliabilities Total | 2.99 | 3.28 | 1.55 |
| Total Long Term Debt | 0.95 | 2.93 | 2.8 |
| Other Long Term Assets Total | 0.5 | 0.88 | 0.9 |
| Note Receivable-Long Term | 0.18 | Not available | Not available |
| Total Current Assets | 120.69 | 86.73 | 73.09 |
| Notes Payable/Short Term Debt | Not available | 10.37 | 10.38 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.65
Price to Sale Ratio1.54
Growth
Debt 5Yr CAGR %26.41
Margins
Operating Margin 12m14.59
Operating Margin 5y Avg14.74
Net Profit Margin 12m11.88
Net Profit Margin 5y12.52
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk50.56
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.8 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,376 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,973 | 1.68 L | 72.73 | — |
| Cipla | INR 1,406.6 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.65 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 68.29%
- FII
- 0.01%
- Other
- 31.70%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Q1 results: HDFC Bank, Axis Bank, Kotak Mahindra among 21 firms on July 18 - Business StandardMarket news · 18 Jul 2026, 9:52 am
Q1 results: HDFC Bank, Axis Bank, Kotak Mahindra among 21 firms on July 18 Business Standard
Markets Rally, But Indo US Bio-Tech Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off - Markets MojoMarket news · 8 Jul 2026, 3:12 pm
Markets Rally, But Indo US Bio-Tech Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off Markets Mojo
Indo Us Bio-Tech Completes Postal Ballot Dispatch and Opens Remote E-Voting - TipRanksMarket news · 5 Jul 2026, 4:25 pm
Indo Us Bio-Tech Completes Postal Ballot Dispatch and Opens Remote E-Voting TipRanks
ALLCARGO GLOBAL LTD. Stock/Share price , NSE/BSE Forecast News and Live Quotes - EquitymasterMarket news · 3 Jul 2026, 7:57 pm
ALLCARGO GLOBAL LTD. Stock/Share price , NSE/BSE Forecast News and Live Quotes Equitymaster
Indo US Bio-Tech Ltd Falls to 52-Week Low of Rs 86 as Sell-Off Deepens - MarketsMojoMarket news · 30 Jun 2026, 4:04 pm
Indo US Bio-Tech Ltd Falls to 52-Week Low of Rs 86 as Sell-Off Deepens MarketsMojo
Q4 results: ITC, Nykaa, LIC, MTNL, Aurobindo Pharma, and 181 more on May 21 - Business StandardMarket news · 21 May 2026, 12:30 pm
Q4 results: ITC, Nykaa, LIC, MTNL, Aurobindo Pharma, and 181 more on May 21 Business Standard
Corporate actions
Events
- annual General MeetingPOM
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsInter-alia, to consider 1. Re-appointment of M/s. Gautam N Associates as a Statutory Auditors of the Company. 2. Approve Notice of Postal Ballot. 3. Other business matters.
- annual General MeetingAGM
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Indo US Bio-Tech
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Indo US Bio-Tech Limited is a specialized agriculture seed company with its own research station, marketing network and seed production bases. The Company operates through the Seed Cultivation, processing and trading segment. It is involved in crop research and development through breeding, production of seeds, processing, packing and marketing of hybrid and open-pollinated varieties of agricultural crops. Its product portfolio includes a diversified variety of agriculture seeds namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, cumin, coriander, and others. It has a distribution network in the states of Gujarat, Maharashtra, Madhya Pradesh, Chhattisgarh, Rajasthan, Punjab and others. It also exports to many countries, namely the United States, New Jersey, Palestine, Cameroon, Kuwait and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- INDOUS
- BSE Code
- 541304
Questions
Stock FAQ
What is the symbol and ISIN of Indo US Bio-Tech?
Indo US Bio-Tech has the symbol INDOUS and ISIN - INE250Z01010.
What is the current price of Indo US Bio-Tech?
Indo US Bio-Tech is currently trading at INR 79.60.
What are the year high and year low of Indo US Bio-Tech?
Indo US Bio-Tech has a year high of INR 205.10 and a year low of INR 70.00.
What is the market capitalization of Indo US Bio-Tech?
Indo US Bio-Tech has a market capitalization of INR 170.53 crore.
What is the P/E ratio of Indo US Bio-Tech?
Indo US Bio-Tech has a P/E ratio of 15.02.
What is the dividend yield of Indo US Bio-Tech?
Indo US Bio-Tech has a dividend yield of 0.00%.
How is the financial performance of Indo US Bio-Tech based on revenue, net income, and EPS?
Indo US Bio-Tech has revenue of INR 110.44 crore, net income of INR 13.12 crore, and EPS of INR 6.54.
What is the book value of Indo US Bio-Tech?
Indo US Bio-Tech has a book value of INR 46.15.
What is the debt-to-equity ratio of Indo US Bio-Tech?
Indo US Bio-Tech has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Indo US Bio-Tech?
Indo US Bio-Tech has a price-to-book ratio of 1.72 and a price-to-sales ratio of 1.54.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.